Does the severity of depressive symptoms after stroke affect long-term survival? An 18-year follow-up

Mónika Kellermann¹, Roland Berecz², Dániel Bereczki³*

¹ Comedicum, Medizinisches Versorgungszentrum, München, Germany, ² Department of Psychiatry, University of Debrecen, Debrecen, Hungary, ³ Department of Neurology, Semmelweis University, Budapest, Hungary

*bereczki.daniel@med.semmelweis-univ.hu

Abstract

Objective
We tested whether the severity of depressive symptoms in acute stroke and 4 years later are predictors of long-time survival.

Method
We evaluated the severity of stroke in 82 patients with acute stroke by the Barthel index, the Scandinavian Stroke Scale and the Orgogozo scale, and we also quantified the severity of depressive symptoms by the Beck and the Hamilton scales in the first week of stroke, in 1995. We re-evaluated the scales 4 years after stroke in 41 out of 48 survivors. We checked the survival status of the initial cohort 18 years after stroke. In the assessment Kaplan-Meier graphs were constructed and the outcomes between groups were compared with log-rank tests.

Results
Clinically important depressive symptoms (≥10 on the Beck scale) was present in 16 patients (19,5%) with acute stroke one week after admission. Case fatality was 41% at 4 years and 84% at 18 years after stroke. Those patients who survived at 4 years were significantly younger (p<0,05). Depressive symptoms in acute stage were not independent predictor of the length of survival. More severe strokes were associated with more severe depressive symptoms 4 years after stroke. In the survival subgroup of patients, those who had more severe depression (≥10 on the Beck scale) at 4 years, had shorter post-stroke survival than those with milder or no depression (Mann-Whitney test, p = 0.022; log-rank test, p = 0.047). In multivariate analyses, adjusted for age, sex, stroke severity and the severity of depressive symptoms, age, sex and stroke severity remained the significant predictors of the length of survival.
Conclusions

The severity of depressive symptoms either in the acute phase or 4 years after stroke is not an independent predictor of the length of survival in an 18-year follow-up.

Introduction

Stroke represents the second most common cause of death worldwide following only coronary heart diseases [1], and it often has diverse, long-term physical and neuropsychological consequences [2]. Stroke is a leading cause of serious long-term disability in the United States [3]. Furthermore, WHO has projected that by 2030 unipolar depressive disorder will become the second leading cause of burden of disease worldwide, as measured by the disability-adjusted life years [4]. Several meta-analyses have confirmed a positive association between depression and the risk of cerebral ischaemic event [5,6].

Data available from 61 studies showed that depressive symptoms were present in 31% (28–35%) of all stroke survivors at any time during follow-up [7]. Ayerbe et al. [8] found similar estimates: the pooled prevalence of poststroke depression (PSD) at any time point was 29%, with a prevalence of 28% within a month of stroke, 31% at 1–6 months, 33% at 6 months to 1 year, and 25% at more than 1 year, respectively.

Depression after stroke is associated with a reduction in rehabilitation treatment efficacy [9,10], limitations in daily life activities [11], and a higher risk of recurrent stroke [12]. Furthermore, poststroke depression was reported to be related to a considerably increased mortality risk [13], the odds ratio of mortality rate can be up 3,4 times in PSD patients compared to non-depressed post-stroke patients [8,14]. The relationship between depression and mortality after stroke seems to be related to the follow-up duration [15]. Although the importance of poststroke psychiatric comorbidity is currently well documented, poststroke depression frequently remains undiagnosed [16].

Many different predictors of PSD were investigated across previous studies. Disability after stroke, cognitive impairment, stroke severity, history of pre-stroke depression, anxiety, and lack of family support were reported as predictors of depression after stroke in previous reviews [9,17]. Furthermore, the country of origin also seems to play a role [18]. The pathogenesis of PSD remains controversy whether PSD is a direct result of neuroanatomical impairment or indirectly due to the patient’s abnormal reaction to a serious cerebrovascular incident [19]. However, long term data (15 years or more) on the relationship between depressive symptoms at the acute phase of stroke and the outcome of patients, measured by mortality, are scarce [20,21].

In a sample of 82 patients from 190 consecutive stroke patients admitted at our department in 1995, depressive symptoms were present in 22 patients (27%) one week after admission, and these patients had a significantly more severe stroke by Barthel, Scandinavian, and Orgogozo, scales (p<0.001) [22]. The aim of the present study was to analyse the presence and severity of depressive symptoms in stroke patients in acute stage as well as 4 years after stroke, and to test whether the severity of depressive symptoms is an independent predictor of case fatality during 18 years following the index stroke.

Methods

Examination in acute stage (</= 7 days after stroke)

During a 4-month period from September 1995 to January 1996, 190 patients with acute ischemic or hemorrhagic stroke were consecutively admitted to our stroke unit. Of these patients,
82 were eligible to be included in the study within one week after admission (Fig 1, for further details see [22]). Written informed consent was obtained from all 82 eligible patients. The study was approved by the local Ethical Committee of the University Medical School of Debre-cen. To quantify the severity of stroke, we used the Scandinavian Neurological Stroke scale (SNSS, scoring range: 0–58, zero being the most severe) [23], the Orgogozo scale (ORG, scoring range 0–100, zero being the most severe) [24], and the Barthel index (BI, scoring range 0–100, zero being the most severe) [25] in the acute stage. The severity of depressive symptoms was evaluated by the 13 items version of the Beck Depression Inventory (BDI-13, scoring range 0–39, 39 being the most severe) [26] and the Hamilton Rating Scale for Depression (HRSD, scoring range 0–52, 52 being the most severe) [27]. The reliability and validity of these scale have been established previously [28–31]. Examination for the study was scheduled for the seventh day after admission, when the eligibility of the patients based on the exclusion and inclusion criteria were evaluated, and the stroke and depression scales were administered. Exclusion criteria were transient ischemic attack; disturbance of the level of consciousness (somnolence, stupor, or coma), severe aphasia or dementia that prevented reliable evaluation of the mood with the applied scales. Patients who died or were discharged before the planned day of examination were also not included. Details of our findings in the acute stage have been previously reported [22].

**Follow-up examinations (4 and 18 years after stroke)**

At four years after stroke, the same investigator (M.K.) personally visited and re-evaluated each patient at his or her home. Four patients could not be traced at their prior address, two patients refused to follow-up, while one patient was unable to adequately cooperate due to severe aphasia. The BI, the SNSS, the ORG and the BDI-13 scores could be evaluated in 41 out of 48 survivors at four years after stroke. Survival status and date of death were checked from the database of the National Health Insurance Fund at 18 years after stroke (Fig 1).

We used the Spearman correlation to evaluate the association between initial stroke severity, age and the severity of depressive symptoms 4 years after stroke. Initial and 4-year values for scale scores were compared by the Wilcoxon matched pairs test, and the association of initial and 4-year score values were evaluated by the Spearman correlation coefficient. Initial age, stroke and depressive symptoms severity of survivors at 4 years and deceased patients were compared by parametric t-test (in case of age) and non-parametric Mann-Whitney test (for scales). Kaplan-Meier curves were constructed, and the log-rank tests were used to compare the survival distributions between patient groups using 2 cutoff values (5 and 10) for the 13-item version of the BDI-13 (where higher scores mean more severe depression) [32]. In multivariate testing by General Lineal Model (GLM), age at stroke onset, sex, a measure of stroke severity (SNSS) and BDI-13 score were entered in the model to identify independent predictors of the length of survival (measured by years). Statistical significance was set at $p < 0.05$. Statistica for Windows v. 11 (StatSoft, Tulsa, OK) was used for data analysis.

**Results**

In the acute stage, 82 patients with acute stroke were included in this study. There were 48 survivors (59%) at 4 years and 13 survivors (16%) at 18 years after stroke. Those patients who survived at 4-years were significantly younger (63,0±13,9 versus 70,0±9,4, $p < 0.05$). The severity of stroke signs and depressive symptoms in those patients surviving at 4 years are presented in Table 1. At 4 years after stroke, scores on the stroke scales as well as on depression scales correlated with both stroke and depressive scores in the acute phase. We found that more severe strokes were associated with more severe depressive symptoms 4 years after stroke (Fig 2).
Fig 1. Patient flowchart.

Table 1. The severity of stroke signs and depressive symptoms in the acute phase, and in survivors 4 years after stroke (n = 41).

| Feature          | In the 1st week after stroke | At 4 years after stroke (n = 41) | P (Wilcoxon matched pairs tests) | Spearman R (p) |
|------------------|------------------------------|---------------------------------|---------------------------------|---------------|
|                  | Total initial sample (n = 82) | Initial value in those who will survive at 4 years (n = 41) |                   |               |
| BI               | 65 ± 34                       | 72 ± 33                         | 86 ± 24                         | 0.002         | 0.55 (<0.001) |
| BDI-13           | 4.4 ± 4.7                     | 4.2 ± 4.9                       | 4.5 ± 4.7                       | 0.7           | 0.47 (0.002)  |
| HRDS             | 5.4 ± 6.9                     | 5.2 ± 6.7                       | 9.2 ± 7.8                       | 0.004         | 0.44 (0.009)  |
| ORG              | 76 ± 24                       | 79 ± 23                         | 87 ± 18                         | 0.002         | 0.64 (<0.001) |
| SNSS             | 45 ± 12                       | 47 ± 12                         | 52 ± 9                          | <0.001        | 0.69 (<0.001) |

Values are mean ± SD

BI = Barthel Index, BDI-13 = Beck Depression Inventory, HRDS = Hamilton Rating Scale for Depression, ORG = Orgogozo scale, SNSS = Scandinavian Neurological Stroke scale

https://doi.org/10.1371/journal.pone.0209157.T001
Those who had a moderate or severe depression (scored ≥10 on the Beck scale) at 4 years had a shorter post-stroke survival than those scoring below 10 (7.2±1.9 vs 12.7±5.1 years, p = 0.022).

Initial stroke severity and the severity of depressive symptoms at 4 years but not in the acute stage were associated with the length of survival after stroke (Spearman R, p<0.05, Table 2).

Although Kaplan-Meier curves suggested shorter survival in those with more severe depressive symptoms (using cutoff values 5 and 10) in the acute stage as well as at 4 years (Figs 3 and 4), in multivariate analyses only age, sex and stroke severity remained significant independent predictors of the length of survival.

Discussion

To our knowledge, only few studies investigated the predictive value of depressive symptoms more than 15 years after stroke [20,21]. In the present study, we found that more severe strokes...
are associated with higher Beck scores at 4 years after stroke. However, the severity of depressive symptoms either in the acute phase or 4 years after stroke is not an independent predictor of the length of survival. Due to the strong effect of stroke severity and age on survival, there was only a trend towards an association between the severity of depressive symptoms after stroke and case fatality.

The predictors of poststroke depression have been studied in the past few decades. Similar to the results of De Ryck [33] and Hermann [34] we found a correlation between stroke severity and depressive symptoms. Systematic reviews on this topic also found that stroke severity is consistently associated with higher rates of depression after stroke [8,17].

A systematic review and meta-analysis of studies found increased/early mortality at follow-up for individuals with PSD [8,15]. Based on a meta-analysis be Bartoli et al. [15] the relationship between depression and mortality after stroke is related to the follow-up duration. The short-term studies (<2 years) did not show a statistically significant association between depression after stroke and mortality; on the other hand, in medium term (2–5 years) follow-ups the association was statistically significant and the analysis of long-term investigations (>5 years) showed some trend [15]. The results of our study showed that the patients who survived at four years were significantly younger and the initial age at the time of the acute stroke was the main predictor of survival. However, in the subgroup of the initial patients’ population who survived at 4 years the severity of depression correlated with the length of survival.

Depression may affect the prognosis and risk of mortality after stroke because stroke patients suffering from depression may be less compliant to treatment [35]. Depression is associated with poor health behaviours (i.e. smoking, physical inactivity, poor diet, lack of medication compliance) which have a negative impact on survival [36]. Furthermore, depression is related to other major comorbidities, such as diabetes, hypertension, neuroendocrine changes (e.g., sympathetic nervous system activation, dysregulation of the hypothalamic-pituitary-

| Predictor                                      | Spearman R (p)       | P by multivariate testing |
|------------------------------------------------|----------------------|---------------------------|
| Age                                            | -0.35 (0.001)        | < 0.001                   |
| Sex                                            | n/a                  | 0.03                      |
| Acute stroke severity (n = 82)                 |                      |                           |
| BI                                             | 0.31 (0.005)         |                           |
| ORG                                            | 0.23 (0.043)         |                           |
| SNSS                                           | 0.26 (0.020)         | 0.005                     |
| Acute symptoms of depression (n = 82)          |                      |                           |
| BDI-13                                         | -0.02 (0.8)          | 0.41                      |
| HRDS                                           | -0.04 (0.7)          |                           |
| Stroke severity at 4 years (n = 41)            |                      |                           |
| Barthel Index                                  | 0.42 (0.007)         |                           |
| Orgogozo                                       | 0.35 (0.025)         |                           |
| SNSS                                           | 0.43 (0.006)         | 0.059                     |
| Symptoms of depression at 4 years (n = 41)     |                      |                           |
| BDI-13                                         | -0.32 (0.04)         | 0.12                      |
| HRDS                                           | -0.33 (0.04)         |                           |

BI = Barthel index, ORG = Orgogozo scale, SNSS = Scandinavian Neurological Stroke scale, BDI-13 = Beck Depression Inventory, HRDS = Hamilton Rating Scale for Depression.

https://doi.org/10.1371/journal.pone.0209157.t002
adrenocortical axis), platelet aggregation dysfunction [37], and immunological, inflammatory changes [38].

Several randomized, double-blind, controlled studies have examined the efficacy of pharmacotherapies in PSD. In a network meta-analysis paroxetine was found to be the most effective, followed by imipramine, reboxetine, nortriptyline, citalopram and fluoxetine [39].

Jorge et al. [40] could show that treatment with antidepressants, fluoxetine or nortriptyline, for 12 weeks during the first 6 months after stroke significantly increased the survival of both depressed and non-depressed patients. Additionally, a multicenter randomised controlled trial found, that citalopram reduced disability and cardiovascular mortality following stroke [41].

Fig 3. Kaplan-Meier graph of survival in those with Beck Depression Inventory score cutoff values of 5 (A) and 10 (B) in the acute stage (n = 82). BDI-13 = Beck Depression Inventory.

https://doi.org/10.1371/journal.pone.0209157.g003
in a meta-analysis published by Salter et al. [42], the results showed that the early initiation of antidepressant therapy in non-depressed stroke patients might reduce the odds for development of poststroke depression. Finally, problem-solving therapy for 1 year after the stroke increased the time to mortality in a long-term follow up [43].

These findings suggest that the pathophysiological processes determining the increased mortality risk might be associated with poststroke depression.

A major limitation of this study is the relatively small sample size of our patient group, however, the prospective nature of the study, and the use of standardized scales for the evaluation of both stroke and depression severity increase the reliability of the data. The results of the study are also strengthened by the repeated evaluation of the patients 4 years after stroke, as well

Fig 4. Kaplan-Meier graph of survival in those with Beck Depression Inventory score cutoff values of 5 (A) and 10 (B) at 4 years after stroke (patient subgroup survived at 4 years, n = 41). BDI-13 = Beck Depression Inventory.

https://doi.org/10.1371/journal.pone.0209157.g004
as the uniquely long duration with a low (<3%) rate of loss to follow-up regarding survival data. Another limitation was the relatively high number of patients who were excluded from the study in the acute phase. Those patients, who had a severe stroke and died before the planned day of examination were not included, similarly those who had mild stroke symptoms and were discharged before day 7. The study therefore excluded the most severe and milder cases (for detailed analysis see [22]). However, the tested population was therefore more homogenous and most relevant for the long-term evaluation of the outcome status after stroke. At 4-year follow-up seven patients either could not be traced at their permanent or temporary address or refused to consent to the follow-up. We cannot exclude that these patients might have different characteristics compared to the tested population regarding their depression status.

Further research is needed to clarify the association between poststroke depression, mortality after stroke and related pathophysiological processes. Secondly, the effectiveness of pharmacotherapy and psychotherapy for preventing and treating poststroke depression should be explored.

**Conclusion**

In an 18-year follow-up of an initial cohort of acute stroke patients, we found that more severe strokes were associated with more severe depressive symptoms 4 years after stroke. Those who had more severe depressive symptoms at 4 years had a shorter post-stroke survival. In multivariate analyses only age, sex and stroke severity remained significant predictors of the length of survival. The severity of depressive symptoms either in the acute phase or 4 years after stroke may not be an independent factor of the length of survival in an 18-year follow-up.

**Supporting information**

S1 Table. Individual patient data in xls format.

(XLS)

**Acknowledgments**

The authors declare that there are no conflicts of interest.

**Author Contributions**

**Conceptualization:** Roland Berecz, Dániel Bereczki.

**Formal analysis:** Dániel Bereczki.

**Funding acquisition:** Dániel Bereczki.

**Investigation:** Mónika Kellermann, Roland Berecz.

**Methodology:** Dániel Bereczki.

**Project administration:** Mónika Kellermann.

**Supervision:** Dániel Bereczki.

**Writing – original draft:** Mónika Kellermann, Roland Berecz, Dániel Bereczki.

**Writing – review & editing:** Roland Berecz, Dániel Bereczki.
References

1. GBD 2013 Mortality and Cause of Death Collaborators. Global, regional, and national ages-sex specific all-cause and cause specific mortality for 240 causes of death, 1990–2013: a systematic analysis for Global Burden of Disease Study 2013. Lancet. 2017; 385: 117–171.

2. Bourgeois JA, Hilty DM, Chang CH, Wineinger MA, Servis ME. Poststroke neuropsychiatric illness: an integrated approach to diagnosis and management. Curr Treat Options Neuro. 2004; 6(5):403–420.

3. Centers for Disease Control and Prevention (CDC). Prevalence and most common causes of disability among adults: United States, 2005. MMWR Morb Mortal Wkly Rep. 2009; 58:421–426.

4. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006; 3:e442. https://doi.org/10.1371/journal.pmed.0030442 PMID: 17132052

5. Dong JY, Zhang YH, Tong J, Qin LQ. Depression and risk of stroke: a meta-analysis of prospective studies. Stroke 2017; 43(1):32–37.

6. Pan A, Sun Q, Okereke OI, Rexrode KM, Hu FB. Depression and risk of stroke morbidity and mortality: a metaanalysis and systematic review. JAMA. 2011; 306(11):1241–1249. https://doi.org/10.1001/jama.2011.1282 PMID: 21934057

7. Hackett ML, Pickles K. Frequency of depression after stroke: an updated systematic review and meta-analysis of observational studies. Int J Stroke. 2014; 9(8):1017–1025. https://doi.org/10.1111/ij.s.12357 PMID: 25117911

8. Ayerbe L, Ayis S, Wolfe CD, Ruddle AG. Natural history, predictors and outcomes of depression after stroke: systematic review and meta-analysis. Br J Psychiatry. 2013; 202(1):14–21. https://doi.org/10.1192/bjp.bp.111.107664 PMID: 23284148

9. Kotila M, Numminen H, Waltimo O, Kaste M. Depression after stroke: result of the FINNSTROKE Study. Stroke. 1998; 29(2):368–372. PMID: 9472876

10. Karaahmet OZ, Gurcay E, Avluk OC, Umay EK, Gundogdu I, Ecerkale O, et al. Poststroke depression: risk factors and potential effects on functional recovery. Int J Rehabil Res. 2017; 40(1):71–75. https://doi.org/10.1097/MRR.0000000000000210 PMID: 28099186

11. De Ryck A, Fransen E, Brouns R, Geurden M, Peij D, Mariren P, et al. Psychosocial problems associated with depression at 18 months poststroke. Int J Geriatr Psychiatry. 2014; 29(2):144–152. https://doi.org/10.1002/gps.3974 PMID: 23625635

12. Sibolt G, Curtze S, Melkas S, Pohjasvaara T, Kaste M, Karhunen PJ, et al. Post-stroke depression and depression-executive dysfunction syndrome are associated with recurrence of ischaemic stroke. Cerebrovasc Dis. 2013; 36: 336–343. https://doi.org/10.1159/000355145 PMID: 24193249

13. Razmara A, Valle N, Markovic D, Sanossian N, Oviachele B, Dutta T, et al. Depression is associated with a higher risk of death among stroke survivors. J Stroke Cerebrovasc Dis. 2017; 26(12):2870–2879. https://doi.org/10.1016/j.jstrokecerebrovasdis.2017.07.006 PMID: 28780250

14. Robinson RG, Jorge RE. Post-stroke depression: A review. Am J Psychiatry. 2016; 173(3):221–31. https://doi.org/10.1176/appi.ajp.2015.15030363 PMID: 26684921

15. Bartoli F, Lillia N, Lax A, Cracomo C, Mantero V, Carrà G, et al. Depression after stroke and post-stroke depression-executive dysfunction syndrome are associated with recurrence of ischaemic stroke. Cerebrovasc Dis. 2013; 36: 336–343. https://doi.org/10.1159/000355145 PMID: 24193249

16. El Hussein i N, Goldstein LB, Peterson ED, Zhao X, Pan W, Olson DM, et al. Depression and antidepressant use after stroke and transient ischemic attack. Stroke. 2012; 43(6):1609–1616. https://doi.org/10.1161/STROKEAHA.111.679340 PMID: 23533964

17. Kutulaev MA, Hackett ML. Part II: predictors of depression after stroke and impact of depression on stroke outcome: an updated systematic review of observational studies. Int J Stroke. 2014; 9(8):1026–1036. https://doi.org/10.1111/ij.s.12356 PMID: 25156411

18. Bartoli F, Lillia N, Lax A, Cracomo C, Mantero V, Carrà G, et al. Depression after stroke and post-stroke depression-executive dysfunction syndrome are associated with recurrence of ischaemic stroke. Cerebrovasc Dis. 2013; 36: 336–343. https://doi.org/10.1159/000355145 PMID: 24193249

19. El Hussein i N, Goldstein LB, Peterson ED, Zhao X, Pan W, Olson DM, et al. Depression and antidepressant use after stroke and transient ischemic attack. Stroke. 2012; 43(6):1609–1616. https://doi.org/10.1161/STROKEAHA.111.679340 PMID: 23533964

20. Kutulaev MA, Hackett ML. Part II: predictors of depression after stroke and impact of depression on stroke outcome: an updated systematic review of observational studies. Int J Stroke. 2014; 9(8):1026–1036. https://doi.org/10.1111/ij.s.12356 PMID: 25156411

21. Arwert HJ, Meesters JLL, Bolten J, Balk F, Wolterbeek R, Vliet Vlieland TPM. Poststroke Depression: A long-term problem for stroke survivors. Am J Phys Med Rehabil. 2018; 97(8):565–571. https://doi.org/10.1097/PHM.0000000000000918 PMID: 29509550

22. Deng L, Sun X, Qiu S, Xiong Y, Li Y, Wang L, et al. Pharmacological and psychotherapeutic interventions for management of poststroke depression: A Bayesian network meta-analysis of randomized controlled trials. Medicine (Baltimore) 2017; 96(7): e6100.

23. Ayerbe L, Ayis S, Crichton S, Wolfe CD, Rudd AG. The natural history of depression up to 15 years after stroke: The South London Stroke Register. Stroke. 2013; 44(4):1105–1110. https://doi.org/10.1161/STROKEAHA.111.679340 PMID: 23404719

24. Freak-Poli R, Ikram MA, Franco OH, Hofman A, Tiemer H. depressive symptoms prior to and after incident cardiovascular disease and long-term survival. A population-based study of older persons. Depress Anxiety. 2018; 35(1):18–31. https://doi.org/10.1002 da.22689 PMID: 29172249
22. Kellermann M, Fekete I, Gesztesy I, Csiba L, Kollár J, Sikula J, et al. Screening for depressive symptoms in the acute phase of stroke. Gen Hosp Psychiatry. 1999; 21(2):116–121. PMID: 10228892
23. Scandinavian Stroke Study Group. Multicenter trial of hemodilution in ischemic stroke—background and study protocol. Stroke. 1985; 16(5), 885–890. PMID: 3901425
24. Orgogozo JM. Evaluation of treatments in ischemic-stroke patients. In: Amery WK, ed. Clinical Trial Methodology in Stroke. London, Balliere Tindall; 1989. pp. 35–53.
25. Mahoney Fl, Barthel DW. Functional evaluation: The Barthel index. Md State Med J. 1965; 2:61–65.
26. Beck AT, Beck RW. Screening depressed patients in family practice. A rapid technique. Postgrad Med. 1972; 52(6):81–85. PMID: 4635613
27. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960; 23:56–62. PMID: 14399272
28. de Haan R, Horn J, Limburg M, van der Meulen J, Bossuyt P: A comparison of five stroke scales with measures of disability, handicap and quality of life. Stroke. 1993; 24(8):1178–1181. PMID: 8342193
29. Hantson L, De Keyser J: Neurological scales in the assessment of cerebral infarction. Cerebrovasc Dis. 1994; 4(Suppl. 2):7–14.
30. Gresham GE, Phillips TF, Labi ML: ADL status in stroke: relative merits of three standard indexes. Arch Phys Med Rehabil. 1980; 61(8):355–358. PMID: 7406673
31. Berg A, Lönnqvist J, Palomäki H, Kaste M. Assessment of depression after stroke: a comparison of different screening instruments. Stroke. 2009; 40(2):523–529 https://doi.org/10.1161/STROKEAHA.108.527705 PMID: 19074478
32. Stukenberg W, Dura JR, Kiecolt-Glaser JK. Depression screening scale validation in an elderly, community-dwelling population. J Consult Clin Psychol. 1990; 58(2):134–138.
33. De Ryck A, Brouns R, Fransen E, Geurden M, Van Gestel G, Wissens I, et al. A prospective study on the prevalence and risk factors of poststroke depression. Cerebrovasc Dis Extra. 2013; 3(1):1–13. https://doi.org/10.1159/000345557 PMID: 23626594
34. Herrmann N, Black SE, Lawrence J, Szekely C, Szalai JP. The Sunnybrook Stroke Study: a prospective study of depressive symptoms and functional outcome. Stroke. 1998; 29(3):618–624. PMID: 9506602
35. Dossa A, Glickman ME, Berlowitz D. Association between mental health conditions and rehospitalization, mortality, and functional outcomes in patients with stroke following inpatient rehabilitation. BMC Health Serv Res. 2011; 11:311. https://doi.org/10.1186/1472-6963-11-311 PMID: 22085779
36. Shimbo D, Chaplin W, Crossman D, Haas D, Davidson KW. Role of depression and inflammation in incident coronary heart disease events. Am J Cardiol. 2005; 96(7):1016–1021. https://doi.org/10.1016/j.amjcard.2005.05.064 PMID: 16188535
37. Deng L, Oiu S, Yang Y, Wang L, Li Y, Lin J, et al. Efficacy and tolerability of selective serotonin reuptake inhibitors for post-stroke depression: a network meta-analysis. Oncotarget. 2018; 9(34):23718–23728. https://doi.org/10.18632/oncotarget.23891 PMID: 29805769
38. Robinson RG, Jorgensen JS, Madsen M. Long-term mortality after stroke and poststroke depression. Am J Psychiatry. 2003; 160(10):1823–1829. https://doi.org/10.1176/appi.ajp.160.10.1823 PMID: 14514497
39. Kraglund KL, Mortensen JK, Grove EL, Johnsen SP, Andersen G. TALOS: a multicenter, randomized, double-blind, placebo-controlled trial to test the effects of citalopram in patients with acute stroke. Int J Stroke. 2015; 10(6):965–7. https://doi.org/10.1111/ijs.12485 PMID: 25854537
40. Salter KL, Foley NC, Zhu L, Jutai JW, Teasell RW. Prevention of poststroke depression: does prophylactic pharmacotherapy work? J Stroke Cerebrovasc Dis. 2013;(8):1243–51. https://doi.org/10.1016/j.jstrokecerebrovasdis.2012.03.013 PMID: 22554569
41. Robinson RG, Jorge RE, Long J. Prevention of poststroke mortality using problem-solving therapy or escitalopram. Am J Geriatr Psychiatry. 2017; 25(5):512–519 https://doi.org/10.1016/j.jagp.2016.10.001 PMID: 28029510